The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: Role of ERCC1 expression.
Jing Huang
No relevant relationships to disclose
Yi Zhou
No relevant relationships to disclose
Tao Qu
No relevant relationships to disclose
Hong-Tu Zhang
No relevant relationships to disclose
You-Sheng Mao
No relevant relationships to disclose
Hong-Xia Zhu
No relevant relationships to disclose
Lan-Ping Quan
No relevant relationships to disclose
Pu-Yuan Xing
No relevant relationships to disclose
Jin-Wan Wang
No relevant relationships to disclose
He Jie
No relevant relationships to disclose
Ning-Zhi Xu
No relevant relationships to disclose